MEI Pharma is a San Diego-based clinical-stage pharmaceutical company committed to the development and commercialization of novel, best-in-class, cancer therapies intended to improve outcomes for patients. Our approach is to fully understand and leverage the mechanisms and properties of our drug candidates to optimize the balance between efficacy and tolerability to best meet the needs of patients with cancer. Each of our pipeline candidates has a unique mechanism of action that can target pathways involved in driving various hematological malignancies and/or solid tumors. Zandelisib (formerly called ME-401) is in multiple ongoing clinical trials evaluating patients with B-cell malignancies intended to support marketing approvals with the FDA and other regulatory authorities globally. Voruciclib, a potent inhibitor of CDK9, is a clinical stage drug candidate being explored in combination with standard therapies for the treatment of hematologic malignances and solid tumors. ME-344, a mitochondrial inhibitor, is a clinical stage drug candidate being evaluated for the treatment of solid tumors. We are committed to pursuing our company mission in a manner that upholds our workplace values of dedication, shared commitment, personal accountability, mutual trust and fiscal discipline. Interested in joining our team of friendly, dedicated, experienced and collaborative professionals? Visit meipharma.com/careers for more details.
View Top Employees from MEI PharmaWebsite | http://www.meipharma.com |
Ticker | MEIP |
Revenue | $4 million |
Funding | $15.6 million |
Employees | 142 (106 on RocketReach) |
Founded | 2000 |
Address | 11455 El Camino Real Suite 250, San Diego, California 92130, US |
Phone | (858) 369-7100 |
Technologies |
JavaScript,
HTML,
Google Analytics
+23 more
(view full list)
|
Industry | Biotechnology Research, Pharmaceuticals, Biotechnology, Healthcare, Drug Discovery |
Web Rank | 5 Million |
Keywords | Mei Pharma, Mdx-1106 Dose Escalation Korea, Meip Clinical Trial, Mei Pahrma, Mei Pharma Inc |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies |
Looking for a particular MEI Pharma employee's phone or email?
The MEI Pharma annual revenue was $4 million in 2024.
David Urso is the President and Chief Executive Officer of MEI Pharma.
106 people are employed at MEI Pharma.
MEI Pharma is based in San Diego, California.
The NAICS codes for MEI Pharma are [325, 3254, 32541, 32].
The SIC codes for MEI Pharma are [283, 28].